At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, it was a pleasure to meet Dr Maisnam again, to catch up on the latest knowledge and insights on the growing epidemic of diabetes in India.
1. How does diabetes in Indian patients differ from that from Western populations? (0:04)
2. What factors influence ethnic differences in the relationship between obesity and diabetes? (0:43)
3. How can we target adipose tissue to improve weight management? (1:43)
4. What factors should be considered when selecting glucose-lowering agents in obese patients? (2:38)
5. What are you most looking forward to at this year’s EASD meeting? (3:33)
Indira Maisnam has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!